Cascade recently announced thatthe new FXR agonist CS0159, jointly developed by the team of Eric Xu, founder of Shanghai Institute of Medicine, and Li Jia, team of Shanghai Institute of Medicine, is aimed at NASH-CS0159-002 carried out in the United States for non-alcoholic fatty liver disease
Recently, Cascade announced that the new FXR agonist CS0159 jointly developed by Eric Xu, the founder of the company, and Li Jia, the founder of the Shanghai Institute of Pharmacy, won the qualification of the Fast Track of the US Food and Drug Administration (FDA) for the treatment of patients with
Recently, Cascade announced that the new FXR agonist CS0159, jointly developed by Eric Xu, the founder of the company, and Li Jia, the team of the Shanghai Institute of Pharmacy, has obtained the implied permission of the US Food and Drug Administrat
On December 7, 2021, Cascade Pharmaceuticals, Inc announced that the new class I drug CS0159 developed by the company had completed the first administration to the subjects.Dr. Eric Xu, founder of the company, said:"With the efficient cooperation of the Cascade team, CS0159 soon reached the mil
On October 23, 2021, Dr. Eric Xu, founder of Cascade, was invited to attend the 13th "Tan Jiazhen Life Science Award" and won the 13th "Tan Jiazhen Life Science Achievement Award".Above: a group photo of the participants. Dr. Xu Huaqiang is in the third row on the rightAbove: 2 o
沪ICP备88888888号
